Monthly Archives: May 2019

Inhibition of cell growth and down-regulation of telomerase activity by amygdalin in human cancer cell lines

This research demonstrated the mechanism in which cancer could be killed off with amygdalin.

by   Ji-Yoon Moon, Sang-Won Kim, Gi-Mok Yun, Hyeon-Sik Lee, Yoon-Dong Kim, Gie-Joon Jeong, Imran Ullah, Gyu-Jin Rho & Byeong-Gyun Jeon

The purpose of this study was to examine the effect of amygdalin on cell growth and telomerase activity in human cancer and MRC-5 fibroblast cell lines. The level of β-glucosidase activity for releasing cyanide was significantly (P < .05) higher in cancer cell lines (A-549, MDA-MB-231, MCF-7 and U87-MG) than in MRC-5 fibroblasts. Growth rate of cancer cells was apparently inhibited in concentrations above 10 mg/ml amygdalin with senescent-like abnormal morphology. Whereas the effects were absent or marginally detected in MRC-5 fibroblasts. High incidence of β-galactosidase activity was observed in amygdalin-treated cancer cells, compared with that of untreated control while no difference was observed between the control and amygdalin-treated MRC-5 fibroblasts. Furthermore, level of telomerase activity was significantly (P < .05) higher (∼8–13 fold) in cancer cell lines along with high expression of telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC) than in MRC-5 fibroblasts which did not expressed TERT and TERC. However, telomerase activity was significantly (P < .05) down-regulated in amygdalin-treated cancer cells with the decreased expression of TERT and TERC compared with control cancer cells. There were no difference in the telomerase activity between control and amygdalin-treated MRC-5 fibroblasts. Based on these observations, we concluded that amygdalin treatment offers a valuable option for the cancer treatment, causing inhibition of cell growth and down-regulation of telomerase activity in human cancer cell lines by increasing β-glucosidase activity.

Keywords: Humancancer cellscell growthsenescencetelomerase activity